Dr. Alistair Ingram, Director of the Division of Nephrology at McMaster University, will be giving a talk at St. Joseph's Healthcare Hamilton on Sunday about possible treatments for Autosomal Dominant Polycystic Kidney Disease (ADPKD), a genetic kidney disease which affects an estimated 1 in 500 people.
"With the breaking news about the promising clinical trial results for tolvaptan, an investigational drug for the treatment of ADPKD, Dr. Ingram's update on vaptans, among others, could no be more timely," said Shiona Mackenzie-Morrison, the Hamilton Chapter Coordinator of the PKD Foundation of Canada.
"The information about tolvaptan is probably the most exciting news in the past decade for PKD patients, but it is not the only option scientists are working on. PKD patients are interested in finding out as much as possible about what's happening in the field of kidney research and Dr. Ingram's talk on November 18 offers an amazing opportunity to learn more. For non-scientists, it's really helpful to be able to ask an expert questions in person, because research studies can be quite intimidating to read."
Dr. Ingram is a Clinical Doctor with the Hamilton Centre for Kidney Research and has research interests in mechanisms of kidney scarring and diabetic kidney disease. Dr. Ingram started practice at McMaster in 1996 and became a full Professor of Medicine in 2009.
Dr. Ingram's presentation is part of an ongoing series of two-hour informational support meetings hosted by the Hamilton Chapter of the PKD Foundation of Canada. They are open to the public and free of charge. The venue is accessible.